Predictive Oncology Inc. (Nasdaq: POAI) reported its financial results for the first quarter of 2025, ending March 31. The company recorded total revenue of $110,310, a significant increase from the $4,858 reported during the same period in 2024. This rise in revenue was primarily attributed to the completion of a tumor-specific 3D model within the quarter. The company reported a loss from continuing operations of approximately $2.3 million. Basic and diluted loss per common share from continuing operations for the quarter was $0.32, compared to $0.88 for the same period in 2024. Predictive Oncology concluded the quarter with $3.1 million in cash and cash equivalents, a substantial increase from $611,822 as of December 31, 2024. The company also reported an improved Stockholder's Deficit compared to December 31, 2024. During the first three months of 2025, Predictive Oncology received more than $3.1 million in combined gross proceeds from the sale to DeRoyal and issuance of common stock. The company also partnered with Switzerland-based Tecan Group Ltd. to expand high-throughput drug screening capabilities, which was showcased at the 2025 Society for Laboratory Automation and Screening International Conference & Exhibition in San Diego, CA. The company is exploring potential partnerships with leading biopharmaceutical companies to leverage its artificial intelligence and machine learning platform for drug repurposing in new cancer indications.